



The AIDS Clinical Trials Group (ACTG) Network is the largest HIV/AIDS clinical trials organization in the world. We currently have 34 domestic & 25 international sites.



## ACTG Network Clinical Trial Update: A5366

### **Protocol A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors (the MOXIE trial)**

Women bear half the burden of HIV infections worldwide and it is critical that any interventions developed to try to cure HIV are effective in both women and men. However, without studying women specifically, researchers simply cannot be confident new treatments will be as effective in them versus their male counterparts. Therefore, identifying and examining biological differences between women and men living with HIV will assist researchers in discovering new immune responses and provide new approaches to cure research. One important biological difference between women and men is related to the sex hormone estrogen. Recent research has shown that estrogen can directly influence the activity of the HIV virus in cells (Karn et al., International AIDS Society meeting, Vancouver, 2015). The presence of estrogen in women may therefore influence certain strategies being studied to work towards an HIV cure. One therapeutic approach to address this difference is to block the estrogen receptor, to try to increase the activity of other medications targeting the HIV virus. As there is extensive clinical experience using estrogen receptor blocker medications that are safe and effective treatments for breast cancer, researchers were intrigued. With this in mind, Protocol A5366: Selective

Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors (the MOXIE trial) was developed by a team of ACTG Network researchers led by Protocol Co-Chairs Eileen Scully, MD, PhD, of the Johns Hopkins University Clinical Research Site and Rajesh Gandhi, MD, of the Massachusetts General Hospital Clinical Research Site. [Read more>>](#)

---

## 2018 Annual ACTG Network Meeting Update

### Registration Now Open for the 2018 Annual ACTG Network Meeting

The 2018 Annual ACTG Network Meeting will be held Wednesday, June 20 through Sunday, June 24 in Washington, DC, at the Omni Shoreham Hotel. The meeting includes Principal Investigators, Site Investigators and Site Coordinators, Research Nurses, Laboratory Technologists, Pharmacists, Data Managers, Community Representatives, Specialty Laboratory Directors and representatives from the Leadership and Operations Center, Network Coordinating Center, Statistical and Data Management Center and DAIDS.

To register for the 2018 Annual ACTG Network Meeting, [click here](#).

Please note that the session-specific agendas will be available on the ACTG Network Member website mid-June. An important reminder message about meeting details will be distributed approximately one week prior to the meeting.

Registrants with questions related to lodging should contact [actg.meetings@fstrf.org](mailto:actg.meetings@fstrf.org).

---

## Guest Blog: New Ideas from the Outreach, Recruitment and Retention Working Group

### Spring Clean your Recruitment and Retention with Free Resources!

*by Anna Benbrook, OR&R Working Group Member*

When we think of marketing and communications, usually our mind goes to large teams in swanky ad agencies that are incredibly expensive, but that does not have to be the case. There are several free resources to assist with making your outreach, recruitment and retention efforts stand out among the rest.

Not sure where to even start? Need suggestions for inspiration, photos, graphic design and fonts? Well, then this article is for you! [Read more>>](#)

---

## REPRIEVE Trial Increases Enrollment Goals

## **REPRIEVE to Enroll Additional 1000 Study Participants**

Since the launch of REPRIEVE, a Randomized Trial to Prevent Vascular Events in HIV, the protocol team has worked diligently to meet enrollment milestones. The REPRIEVE team is pleased to announce that they are going strong, with almost 6,500 participants enrolled across 118 sites. Having extended enrollment to 7,500, and one extra year, the team is looking forward to finishing up enrollment soon. Retention is becoming a major focus now as target enrollment is in sight!

"We are thrilled that REPRIEVE is achieving significant enrollment milestones. We would like to thank each and every one of our study participants and express our gratitude for the huge effort by so many people all over the world to help us reach our lofty enrollment goals." said Dr. Steven Grinspoon, REPRIEVE Principal Investigator, Massachusetts General Hospital Clinical Research Site.

---

## The HAILO Connection Newsletter


### **Latest Edition of Protocol A5322/HAILO Study Participant Newsletter Now Available**

In the current issue of the HAILO Connection, learn updates regarding recent reports from HAILO researchers. These include a recent presentation that profiled associations between frailty, disability and certain common health conditions. From the same meeting, other research described participant characteristics that were found to be associated with greater risk for cognitive (thinking and memory) problems. These reports and others represent a vital part of HAILO's ongoing mission to evaluate health and quality-of-life factors associated with healthy aging. The HAILO team remains committed to providing up-to-date findings and to producing cutting-edge research that will contribute to the goal of achieving and maintaining superb health among persons aging with HIV. To read the latest edition of the HAILO Connection, [click here](#).



---

## This Moment in HIV/AIDS History



Pedro Zamora  
photo credit: MTV

### **June 30, 1994: "Real World: San Francisco," Premieres on MTV Featuring Pedro Zamora who was Living with HIV**

On June 30, 1994, fans were first introduced to Pedro Zamora, the young Cuban-American on "Real World: San Francisco" who was living with HIV. Viewers came to know him as a man determined to educate others and fight against the stigma associated with HIV. While his fellow cast members bickered,

and flirted and partied like regular twenty-somethings, Pedro battled HIV at a time when treatments were limited and ignorance was epidemic. Throughout the season, viewers tuned in to see Pedro's pioneering story unfold as cameras filmed everything from his educational keynotes to his union with his partner.

"When we cast Pedro, we knew he was someone special, but we had no idea the impact he would have on our society, our culture and putting a face on HIV/AIDS. We're proud to have helped introduce him to the world, and we're proud that over 20 years later, his impact is still being felt," said Real World co-creator Jonathan Murray in an interview.

To learn more about this moment in HIV history, [click here](#).



Thank you for taking the time to read the ACTG Network's Monthly Newsletter. If you would like to be a guest blogger, have your clinical research site highlighted or would like to nominate a colleague for the Spotlight, please [click here](#). We welcome your feedback.

Sincerely,

**Patrick Bayhille**

**Senior Research Communications Specialist**

**AIDS Clinical Trials Group Network**

[VISIT OUR WEBSITE](#)



Like us on Facebook

Follow us on [twitter](#)

Copyright © 2018. All Rights Reserved.

AIDS Clinical Trial Group (ACTG) Network,  
900 Commonwealth Avenue, Boston, MA 02115